Home » Stocks » RPHM » Company

Reneo Pharmaceuticals, Inc. (RPHM)

Stock Price: $13.89 USD -1.11 (-7.40%)
Updated Apr 9, 2021 4:00 PM EDT - Market closed
Reneo Pharmaceuticals, Inc.
Founded 2014
IPO Date Apr 9, 2021

Stock Information

Ticker Symbol RPHM
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency US Dollars
IPO Price $15.00
CIK Code 1637715
Employer ID 47-2309515

Company Description

Reneo is a clinical stage pharmaceutical company focused on the development of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP).

Reneo Pharmaceuticals is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes.

We are initially developing REN001 in three rare genetic diseases that typically present with myopathy and have high unmet medical needs: primary mitochondrial myopathies (PMM), long-chain fatty acid oxidation disorders (LC-FAOD), and glycogen storage disease type V (McArdle disease).

We completed an open-label Phase 1b clinical trial in patients with PMM and, based on the results, initiated a global, randomized, double-blind, placebo-controlled Phase 2b clinical trial in patients with PMM and plan to begin enrollment in the first half of 2021.

We are also conducting two open-label Phase 1b clinical trials of REN001 in patients with LC-FAOD and with McArdle disease and we anticipate results in the first half of 2022.

We also plan to explore the potential of REN001 in other rare diseases, such as Duchenne muscular dystrophy and Alport syndrome.

Key Executives

Gregory J. FlesherPresident, Chief Executive Officer and Director
Wendy JohnsonChief Development Officer
Alejandro Dorenbaum, M.D.Chief Medical Officer
Vineet R. JindalChief Financial Officer
Michael CruseSenior Vice President, Corporate Operations
Michael GreyExecutive Chairman
Lon Cardon, Ph.D.Director
Eric M. Dube, Ph.D.Director